Company: CMND
Filing Date: 2025-11-26
Form Type: 6-K
Source: 0001213900-25-115110
Chunk: 1

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: 6-K
Chunk 1
---
 satisfaction of customary closing conditions. The aggregate gross proceeds to the Company are expected to be approximately $1.294
million. The Company expects to use the net proceeds from the Offering, together with its existing cash, for general corporate purposes,
which may include operating expenses, research and development, including clinical and pre-clinical testing of our product candidates,
working capital, future acquisitions and general capital expenditures.

The Securities Purchase Agreement
also contain representations, warranties, indemnification and other provisions customary for transactions of this nature.

The
securities described above and to be issued in the Offering are being issued pursuant to a prospectus supplement dated as of November
26, 2025, which will be filed with the Securities and Exchange Commission, in connection with a takedown from the Company’s shelf
registration statement on Form F-3 (File No. 333-275991) (the “Registration Statement”), which became effective on December
26, 2023, and the base prospectus dated as of December 26, 2023 contained in such Registration Statement. This Report on Form 6-K (this
“Report”) shall not constitute an offer to sell or the solicitation to buy, nor shall there be any sale of, any of the securities
described herein in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.

Copies of the Securities
Purchase Agreement and the Pre-Funded Warrant are filed as Exhibits 10.1 and 10.2, respectively, to this Report and are incorporated
by reference herein. The foregoing summaries of such documents are subject to, and qualified in their entirety by reference to, such
exhibits.

Copies
of the opinions of Daniel N. Bloch and Greenberg Traurig, P.A. relating to the securities issued in the Offering are attached as Exhibits
5.1 and 5.2, respectively.

This Report, excluding Exhibit
99.1, is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293)
and Form S-8 (File No. 333-283695),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.

Forward Looking